Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 4.33T |
| Revenue (ttm) | 549.64B |
| Net Income (ttm) | 104.50B |
| Shares Out | 2.40B |
| EPS (ttm) | 43.55 |
| PE Ratio | 41.45 |
| Forward PE | 36.47 |
| Dividend | 16.00 (0.88%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 1,777,401 |
| Average Volume | 1,893,704 |
| Open | 1,819.00 |
| Previous Close | 1,818.30 |
| Day's Range | 1,800.20 - 1,820.20 |
| 52-Week Range | 1,548.00 - 1,910.00 |
| Beta | 0.25 |
| RSI | 63.65 |
| Earnings Date | Feb 4, 2026 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, NSE:SUNPHARMA's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Nifty 50 top losers today, December 1: Max Healthcare, InterGlobe Aviation, Bajaj Finance, Sun Pharma, Adani Enterprises and more
Indian equity benchmarks spent much of the December 1 session moving within a narrow band, eventually closing almost unchanged. The...
Sun Pharma launches Ilumya in India for moderate-to-severe plaque psoriasis – clinical data shows strong long-term efficacy
Sun Pharmaceutical Industries Ltd has officially introduced its global innovative biologic Ilumya® (Tildrakizumab) in India for the treatment of moderate-to-severe...
Nifty 50 top gainers today, November 28: Mahindra & Mahindra, Sun Pharmaceutical, Adani Enterprises, Dr. Reddy’s Laboratories and more
Indian equity benchmarks ended almost unchanged on November 28. The Sensex slipped 0.02% to close at 85,706.67, while the Nifty...
Morgan Stanley bullish on Sun Pharma as FDA approval supports stronger specialty momentum
Morgan Stanley has reiterated its overweight stance on Sun Pharma with a target price of ₹2,026 per share after the...
Sun Pharma announces FDA approval for updated UNLOXCYT label based on long-term clinical data
Sun Pharmaceutical Industries Ltd has announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for...
AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India
AstraZeneca Pharma India shares rose more than 3% in morning trade after the company, along with Sun Pharmaceutical Industries, announced...
AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India
AstraZeneca Pharma India and Sun Pharmaceutical Industries have joined hands once again, announcing a second brand partnership to expand the...
Why are Sun Pharma shares falling today? Explained
Shares of Sun Pharmaceutical Industries Ltd fell to Rs 1,712.20 on Tuesday after the company’s partner Philogen S.p.A. announced that its...
Sun Pharma’s partner Philogen reports positive survival trends in Fibromun Phase III study for soft tissue sarcoma
Shares of Sun Pharmaceutical Industries will be in focus on Wednesday, November 12, after the company announced that its partner...
Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward
Nomura has upgraded Sun Pharma to a buy call with a target price of ₹1,960 per share, implying a potential...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst US Market Challenges
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeut...
Stocks to Watch Today, October 9: HFCL, Coal India, Prestige Estates, GR Infra, Lupin, Senco Gold, Saatvik Green, Adani Power, Sun Pharma in focus
Indian equities are set for a stock-specific session on Thursday, October 9, 2025, as several companies announced project wins, business...
Sun Pharma shares rally nearly 3% as Citi reiterates ‘Buy’ rating, says pricing overhangs now resolved after Pfizer deal
Sun Pharmaceutical Industries Ltd. shares surged nearly 3% on strong investor sentiment after Citi reiterated its buy rating for the stock, setting a target price of ₹2,180 per share. The brokerage hi...
[Brokerage Calls] Stocks to watch on October 1: Ultratech Cement, Muthoot Finance, Manappuram Finance, Amber, Syrma SGS, Sun Pharma and more
Brokerages have released a fresh set of recommendations across cement, gold financiers, consumer, pharma, and technology sectors. The tone remains largely positive with selective neutral calls as mark...
Citi bullish on Sun Pharma shares, says MFN and pricing overhangs now resolved after Pfizer deal
Citi has reiterated its buy rating on Sun Pharmaceutical Industries with a target price of ₹2,180 per share, noting that key overhangs related to trade and pricing risks have eased significantly. The ...
Stock Market Live Updates Today, October 1: Adani Enterprises, Power Grid, Adani Green, L&T Technology in focus
Welcome to Business Upturn’s live coverage of the Indian stock market on October 1 2025. The trading session is expected to remain stock-specific as several companies announced key developments. In fo...
Top stocks to watch today, October 1: Adani Enterprises, Sun Pharma, L&T Technology, Adani Green and more
As the market opens on October 1, several major companies are in focus following fresh announcements, regulatory approvals, and business developments. Here are the top stocks investors should track to...
Trump's 100% tariffs on branded drugs: Indian generics spared but poses risks for pharma sector – Explained
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers are largely unaffe...
Not a med emergency: Generic pharma cos spared from harm
Trump's new 100% pharma levy primarily targets branded and patented medicines, potentially impacting Sun Pharma and Biocon's US sales. While most Indian generic firms anticipate business as usual, som...
Trump’s 100% tariffs on branded drugs: Which Indian pharma stocks are most vulnerable? Experts weigh in
Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports.
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zyd...
Sun Pharma falls nearly 3% as Trump’s 100% tariff on pharma imports spooks sector
Shares of Sun Pharmaceutical Industries Ltd dropped 2.61% to ₹1,585 in Friday’s early trade, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented ...